Financial Express (Holdings) Limited (“we”, “our”, “us” and derivatives) are committed to protecting and respecting your privacy. This Privacy Policy, together with our Terms of Use, sets out the basis on which any personal data that we collect from you, or that you provide to us, will be processed by us relating to your use of any of the below websites (“sites”).


For the purposes of the Data Protection Act 1998, the data controller is Trustnet Limited of 2nd Floor, Golden House, 30 Great Pulteney Street, London, W1F 9NN. Our nominated representative for the purpose of this Act is Kirsty Witter.


We collect information about you when you register with us or use any of our websites / services. Part of the registration process may include entering personal details & details of your investments.

We may collect information about your computer, including where available your operating system, browser version, domain name and IP address and details of the website that you came from, in order to improve this site.

You confirm that all information you supply is accurate.


In order to provide personalised services to and analyse site traffic, we may use a cookie file which is stored on your browser or the hard drive of your computer. Some of the cookies we use are essential for the sites to operate and may be used to deliver you different content, depending on the type of investor you are.

You can block cookies by activating the setting on your browser which allows you to refuse the setting of all or some cookies. However, if you use your browser settings to block all cookies (including essential cookies) you may not be able to access all or part of our sites. Unless you have adjusted your browser setting so that it will refuse cookies, our system will issue cookies as soon as you visit our sites.


We store and use information you provide as follows:

  • to present content effectively;
  • to provide you with information, products or services that you request from us or which may interest you, tailored to your specific interests, where you have consented to be contacted for such purposes;
  • to carry out our obligations arising from any contracts between you and us;
  • to enable you to participate in interactive features of our service, when you choose to do so;
  • to notify you about changes to our service;
  • to improve our content by tracking group information that describes the habits, usage, patterns and demographics of our customers.

We may also send you emails to provide information and keep you up to date with developments on our sites. It is our policy to have instructions on how to unsubscribe so that you will not receive any future e-mails. You can change your e-mail address at any time.

In order to provide support on the usage of our tools, our support team need access to all information provided in relation to the tool.

We will not disclose your name, email address or postal address or any data that could identify you to any third party without first receiving your permission.

However, you agree that we may disclose to any regulatory authority to which we are subject and to any investment exchange on which we may deal or to its related clearing house (or to investigators, inspectors or agents appointed by them), or to any person empowered to require such information by or under any legal enactment, any information they may request or require relating to you, or if relevant, any of your clients.

You agree that we may pass on information obtained under Money Laundering legislation as we consider necessary to comply with reporting requirements under such legislation.


We want to ensure that the personal information we hold about you is accurate and up to date. You may ask us to correct or remove information that is inaccurate.

You have the right under data protection legislation to access information held about you. If you wish to receive a copy of any personal information we hold, please write to us at 3rd Floor, Hollywood House, Church Street East, Woking, GU21 6HJ. Any access request may be subject to a fee of £10 to meet our costs in providing you with details of the information we hold about you.


The data that we collect from you may be transferred to, and stored at, a destination outside the European Economic Area (“EEA”). It may be processed by staff operating outside the EEA who work for us or for one of our suppliers. Such staff may be engaged in, amongst other things, the provision of support services. By submitting your personal data, you agree to this transfer, storing and processing. We will take all steps reasonably necessary, including the use of encryption, to ensure that your data is treated securely and in accordance with this privacy policy.

Unfortunately, the transmission of information via the internet is not completely secure. Although we will do our best to protect your personal data, we cannot guarantee the security of your data transmitted to our sites; any transmission is at your own risk. You will not hold us responsible for any breach of security unless we have been negligent or in wilful default.


Any changes we make to our privacy policy in the future will be posted on this page and, where appropriate, notified to you by e-mail.


Our sites contain links to other websites. If you follow a link to any of these websites, please note that these websites have their own privacy policies and that we do not accept any responsibility or liability for these policies. Please check these policies before you submit any personal data to these websites.


If you want more information or have any questions or comments relating to our privacy policy please email [email protected] in the first instance.

 Information  X 
Enter a valid email address

Allergy Therapeutics (AGY)

  Print      Mail a friend

Tuesday 26 April, 2011

Allergy Therapeutics

FDA Update

RNS Number : 4113F
Allergy Therapeutics PLC
26 April 2011

26 April 2011


Allergy Therapeutics plc

("Allergy Therapeutics" or "the Company")


FDA confirms Clinical Hold will be lifted on all three INDs for Pollinex Quattro products



Allergy Therapeutics plc (AIM: AGY), the fully integrated specialty pharmaceutical company specialising in allergy vaccines, is pleased to announce that following its meeting with the US Food and Drug Administration (FDA) on March 17, 2011, it has received official communication from the FDA stating that the clinical hold on the Investigational New Drug applications (INDs) for the three MATA-MPL© products will be lifted once the protocols have been agreed. As a part of the normal process, the FDA has asked the Company to submit its study protocols to the INDs for further discussions in order to provide review and feedback on the proposed studies.


Manuel Llobet, Chief Executive of Allergy Therapeutics, said:


"We are very pleased to report that a clear path forward has been agreed. We are encouraged that the clinical hold on all three INDs will be lifted, allowing the development programmes for these important products for treatment of allergic rhinoconjunctivitis due to grass, trees and ragweed pollen to restart. It is also encouraging that we will receive comments and feedback on our proposed study protocols from the FDA prior to restarting the development programmes. The Company is now moving ahead to identify a development and commercial partner in the US."


Peter Jensen, Chairman of Allergy Therapeutics, said:


"We expect the commercialisation of Pollinex Quattro in the US and further afield to be transformational for the Company. Allergic rhinoconjunctivitis affects millions of people in the US, with an estimated 2.7 million receiving allergy vaccines annually. According to independent reports, the US market has the potential to be worth $1.5-$2.0 billion a year and the company is well placed to develop products for this exciting new market."


Lawrence DuBuske MD, Clinical Professor of Medicine at George Washington University School of Medicine, Washington, DC, who was the principal investigator for the phase III study of the Company's Grass MATAMPL product, the largest ever allergy immunotherapy study undertaken, said:


"The lifting of the clinical hold on all three INDs is good news and will allow specific injectable short course immunotherapy products to be developed using modern clinical trial methodology. With a course of just four  injections administered ahead of the peak allergy season, compared to the current practice of up to 100 injections administered over 52 to 104 weeks, this new approach promises to transform the way allergy immunotherapy is practiced in the US. The very short course of therapy will increase patient compliance and provide important savings in healthcare costs."




For further information


Allergy Therapeutics

+44 (0) 1903 845 820

Manuel Llobet, Chief Executive Officer

Ian Postlethwaite, Finance Director

Nomura Code Securities

+44 (0) 207 776 1200

Juliet Thompson/ Clare Terlouw

Financial Dynamics

+44 (0) 207 831 3113

Ben Brewerton/ Susan Quigley




About Pollinex® Quattro (MATAMPL)


Pollinex® Quattro is a four injection therapeutic vaccine which is being developed for the treatment of allergic conditions which offers same season relief in as little as three weeks after treatment. It is a family of specific standardised vaccines representing a potentially extensive franchise for Allergy Therapeutics and is a novel entrant in the multibillion dollar global allergy market. It is currently available in Europe on a named patient basis.






This information is provided by RNS
The company news service from the London Stock Exchange

a d v e r t i s e m e n t